“The economic impact associated with cerebrovascular events related to non-valvular atrial fibrillation (NVAF) in Italy: the role of apixaban”, FE, vol. 15, no. 1S, pp. 3–4, Dec. 2014, doi: 10.7175/fe.v15i1s.972.